These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 17459081

  • 1. Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.
    Schwedt TJ, Hentz JG, Dodick DW.
    Cephalalgia; 2007 Jun; 27(6):528-34. PubMed ID: 17459081
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR.
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 4. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C, European BoNTA Headache Study Group.
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.
    Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A.
    Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314
    [Abstract] [Full Text] [Related]

  • 6. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR, Mathew NT, Loder EW, DeGryse R, VanDenburgh AM, BoNTA-009 Study Group.
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM, Schim JD, Chippendale TJ.
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [Abstract] [Full Text] [Related]

  • 8. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG, Diamond S, Diamond M, Urban G.
    Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin type A (BOTOX) for treatment of migraine.
    Binder WJ, Brin MF, Blitzer A, Pogoda JM.
    Semin Cutan Med Surg; 2001 Jun; 20(2):93-100. PubMed ID: 11474749
    [Abstract] [Full Text] [Related]

  • 10. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin in migraine prophylaxis.
    Göbel H.
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [Abstract] [Full Text] [Related]

  • 12. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S, Miller NR, Mejico LJ, Perry JD, Medura M, Freitag SK, Girkin C.
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
    Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW.
    Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
    Sahai A, Khan MS, Dasgupta P.
    J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328
    [Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type A for the treatment of headache: pro.
    Blumenfeld A.
    Headache; 2004 Sep; 44(8):825-30. PubMed ID: 15330834
    [No Abstract] [Full Text] [Related]

  • 16. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG.
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [Abstract] [Full Text] [Related]

  • 17. Botulinum toxin A for the treatment of delayed gastric emptying.
    Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB.
    Am J Gastroenterol; 2008 Feb; 103(2):416-23. PubMed ID: 18070232
    [Abstract] [Full Text] [Related]

  • 18. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.
    Petri S, Tölle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A, Dysport Migraine Study Group.
    Eur Neurol; 2009 Feb; 62(4):204-11. PubMed ID: 19622887
    [Abstract] [Full Text] [Related]

  • 20. Botox therapy for refractory chronic migraine.
    Conway S, Delplanche C, Crowder J, Rothrock J.
    Headache; 2005 Apr; 45(4):355-7. PubMed ID: 15836573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.